ArticleFrontiers in medicine2026
KDM5B recruits FOXG1 to suppress the IFN response, leading to malignant progression and immune evasion in cervical cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer carcinogenesis often exhibits significant heterogeneity, and the molecular mechanisms underlying epithelial cell transformation are not fully understood. Methods: Single-cell RNA sequencing was employed to compare the immune microenvironment of normal cervix and cervical cancer. Immunohistochemistry was applied to measure the expression of KDM5B in patient samples. qPCR and western blot were performed to detect the KDM5B expression and activation of IFN pathway in cell line. Co-immunoprecipitation (COIP), immunofluorescence (IF) and surface plasmon resonance (SPR) are employed to detect the binding between KDM5B and FOXG1. Flow cytometry was conducted to evaluate the immune infiltration of mice tumor. Results: This study reveals that malignant progression in cervical cancer is characterized by substantial DNA damage and marked upregulation of the histone demethylase KDM5B. We also identified a novel regulatory mechanism by which KDM5B recruits the transcriptional repressor FOXG1 to suppress the interferon signaling pathway, thereby promoting malignant behaviors and immune escape in cervical cancer. Targeting KDM5B could effectively enhance anti-tumor immunity. Discussion: These findings provide crucial insights into the biological role of KDM5B in cervical cancer and highlight its potential as a promising therapeutic target for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.